Neoplasms

Symptoms and General Pathology

All Conditions

Nervous System Diseases

Neoplasm Metastasis

Neoplasms, Second Primary

Brain Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Antineoplastic Agents

All Drugs and Chemicals

Temozolomide

Antineoplastic Agents, Alkylating

Alkylating Agents

Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases

The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.

Fractionated Stereotactic Radiotherapy

concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2\*5d, q28d, 6cycles

Jianping Xiao

This clinical trial was designed to investigate the efficiency and toxicity of fractionated stereotactic radiotherapy(FSRT) combined with Temozolomide(TMZ) for refractory brain metastases.

This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of FSRT plus TMZ for refractory brain metastases, which are defined as A: multiple brain metastases(≥3 lesions); B: large brain metastases(with one lesion's volume is no smaller than 6cc or the longest diameter is no shorter than 3cm); C: meningeal metastases.

Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases

Fractionated Stereotactic Radiotherapy Combined With Temozolomide for Refractory Brain Metastases: A Single-arm, Single-center Phase II Trial

defined as no progress of the treated lesions and no distant progress in the brain

Using RTOG9508 criteria, Tumor control is defined as CR+PR+SD

assessed by CTCAE criteria, v4.0 and RTOG criteria of the central nervous system

collect the data of causes of death and analyze

Cancer Foundation, China

Chinese Academy of Medical Sciences

Group A: multiple brain metastases: no less than 3 lesions in the brain Group B: Large Brain Metastases: the volume of lesion is no smaller than 6cc or the maximum diameter of the lesion is no shorter than 3cm Group C:Meningeal Metastases.

Intervention：tomotherapy

Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions\<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.

TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2\*5d, q28d, up to 6cycles.

tomotherapy

This clinical trial was designed to investigate the efficiency and toxicity of tomotherapy for refractory brain metastases.

This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of tomotherapy for refractory brain metastases, which are defined as A: multiple brain metastases(≥3 lesions); B: large brain metastases(with one lesion's volume is no smaller than 6cc or the longest diameter is no shorter than 3cm); C: meningeal metastases.

Tomotherapy for Refractory Brain Metastases

Tomotherapy for Refractory Brain Metastases: a Single Arm, Single Center Phase II Trial

the baseline characteristics and treatment plan can be shared with other researchers when the research paper has been published. The IPD will be sent by email if applied.

Patients undergo HSRS (hypofractionated Radiosurgery) on day 1, consisting in 27 Gray (gy) administered in 3 daily fractions.

Within 1 weeks, patients undergo surgical resection.

Patients undergo surgical resection on day 1. Within 4-6 weeks, patients undergo HSRS (hypofractionated Radiosurgery), consisting in 27 Gray (gy) administered in 3 daily fractions.

HSRS converges multiple radiation beams to deliver a single, large dose of radiation to a discrete tumor target with high precision, thereby minimizing radiation dose to the surrounding normal tissue.

Hypofractionated Radiosurgery (HSRS)

Complete surgical resection of brain lesions with adeguate margins.

Brain metastases surgical resection

Pierina Navarria, MD

Federico Pessina, MD

This is a phase III randomized trial with the aim to compare preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.

The occurrence of BMs is a huge and challenging issue affecting about 20-40% of patients with solid primary tumors. Among these, about 25% of patients harbored large BMs, defined as ≥ 2.1 cm. Single dose SRS, using the dose guidelines suggested by the Radiation Therapy Oncology Group (RTOG) 90-05 study, obtains an unsatisfactory local control (LC) rate ranging from 45-49%. In this subset of patients other treatment pathways have been investigated. In the 1990s, Patchell and colleagues determined that patients with good functional status, and solitary intracranial metastases should undergo surgical resection. Unfortunately, surgery alone is able to control tumor in only 50% of patients, and an adjuvant radiation therapy (RT) is required. For several years, adjuvant whole brain radiation therapy (WBRT) has been considered the standard of cure, but a high risk of impairment in neurological functions was recorded, without an actual benefit on survival. Different RT approaches have been inquired with the aim to reduce neurological toxicity preserving the same brain tumor control. Recent randomized trials showed that single dose SRS on the tumor bed might be a valid, and less toxic alternative to WBRT, although an increased risk of radio necrosis (RN) was noticed when large surgical cavities are treated. In the last years hypofractionated stereotactic radiosurgery (HSRS) has gained interest. Its goal is to reduce the risk of RN compared to single dose SRS, while providing similar, or perhaps, improved LC, probably in relation to the need of reducing the dose prescribed in cases of larger lesions using SRS.

However, there has been increasing evidence that patients treated with postoperative SRS have an increased rates of leptomeningeal disease (LMD) occurrence than what was observed when postoperative WBRT was used as the standard. Several retrospective studies have demonstrated a LMD rates up to 31% in the postoperative SRS setting.

The proposed mechanism of this increased risk is iatrogenic tumor dissemination into the cerebrospinal fluid (CSF) at the time of surgical resection, which was not as apparent when the entire intracranial CSF space was treated with routine postoperative WBRT, but has become more apparent with increasing use of postoperative SRS only. It is important to note that a standardized definition of radiographic LMD does not exist and ascertainment bias as to what constitutes radiographic LMD (vs local or distant meningeal failure as an example) is an unresolved issue.

Due to the perceived drawbacks of postoperative SRS, namely the need for cavity margin expansion due to target delineation uncertainty, the variable postoperative clinical course and potential delay in administering postoperative SRS, and the theoretical risk of tumor spillage into CSF at the time of surgery, investigators began to study the use of preoperative SRS as an alternative paradigm to maximize local control of the resection cavity and minimize neurocognitive detriment associated with WBRT. Preoperative SRS has several potential advantages compared to postoperative SRS consisting in :

* a better target delineation to an intact lesion
* the reduction of normal brain irradiated considering the useless of additional margins
* the potential prevention of any cells spilled during resection
* a greater oxygenation ratio of the intact region
* a sterilization effect
* the resection of the majority of irradiated tissues Based on this background we designed this phase III randomized trial comparing preoperative HSRS to postoperative HSRS in patients with large at least one BMs from solid tumors suitable for surgical resection.

Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases

Phase III Randomized Trial Comparing Preoperative Hypofractionated Radiosurgery (HSRS) to Postoperative Hypofractionated Radiosurgery (HSRS) for Patients With Large Brain Metastases (= 2.1cm) Suitable for Surgical Resection

Rate of LMD occurrence in patients who receive HSRS prior to surgery as compared to patients who receive HSRS after surgery. This assessment will be evaluated through radiological images.

To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of local recurrence. This assessment will be evaluated through radiological images.

To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of brain distant progression. This assessment will be evaluated through radiological images.

To evaluate for patients with brain metastases whether there is improved overall survival for patients who receive HSRS prior to surgery as compared to patients who receive HSRS after surgery.

To evaluate for patients undergone pre-operative as compared to post-operative HSRS whether there is a decreased rate of symptomatic radiation necrosis (RN). RN will be evaluated through radiological images.

To evaluate whether preoperative SRS increases rates of surgical morbidity including postoperative complications such as wound infection, need for longer hospital stays, readmission and eventual delay of systemic treatments

To evaluate quality of life (EORTC QLQ-C30, version 3.0) and neurocognitive functions throught specific questionnaires administered to patients.

Neurocognitive test:

* Token Test (Spinnler e Tognoni, 1987)
* Picture naming of objects (Catricalà 2012) and of actions (Papagno et al., 2020)
* Verbal fluency on phonemic and semantic cue (Novelli et al., 1986)
* Rey's 15 words auditory learning test (Carlesimo et al.,1996)
* Reproduction of the Rey figure (Caffarra et al., 2002)
* Stroop test (Caffarra et al. 2002)
* Trail making test (Giovagnoli et al. 1996)
* Copy of Rey Figure (Cafarra et al., 2002)

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases	NCT02654106	Brain Metastase...	Fractionated St... Temozolomide	18 Years - 75 Years	ChineseAMS
Tomotherapy for Refractory Brain Metastases	NCT03027544	Brain Metastase...	tomotherapy	18 Years - 75 Years	ChineseAMS
Preoperative vs Postoperative Hypofractionated Radiosurgery for Patients With Large Brain Metastases	NCT05545007	Brain Metastase...	Hypofractionate... Brain metastase...	18 Years -	Istituto Clinico Humanitas
Stereotactic Radiotherapy Plus Temozolomide for Refractory Brain Metastases	NCT02654106	Brain Metastase...	Fractionated St... Temozolomide	18 Years - 75 Years	ChineseAMS
Tomotherapy for Refractory Brain Metastases	NCT03027544	Brain Metastase...	tomotherapy	18 Years - 75 Years	ChineseAMS

Spots Global Cancer Trial Database for large brain metastases